Westphalen, Anne

[["dc.bibliographiccitation.firstpage","159"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Arachnology"],["dc.bibliographiccitation.lastpage","162"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Schmidt, Martin H."],["dc.contributor.author","Clough, Yann"],["dc.contributor.author","Schulz, Wenke"],["dc.contributor.author","Westphalen, Anne"],["dc.contributor.author","Tscharntke, Teja"],["dc.date.accessioned","2017-09-07T11:49:57Z"],["dc.date.available","2017-09-07T11:49:57Z"],["dc.date.issued","2006"],["dc.description.abstract","Pitfall traps are widely used to capture arthropods. The type of fluid employed in the traps can affect size and condition of the catch. Direct comparisons of different fluids allow entomologists to avoid suboptimal solutions, and facilitate comparisons between studies using different fluids. We compared capture efficiency and preservation attributes between five fluids in a field experiment with special respect to spiders (Araneae) and ground beetles (Coleoptera, Carabidae). Catches in pure water, ethanol-water and ethanol-glycerin were less well preserved than in brine or ethylene glycol-water. Brine and ethanol-glycerin showed low capture efficiencies, presumably because their high specific density made arthropods float and thereby facilitated escape. Only the mixture of ethylene glycol and water combined good preservation attributes with high capture efficiency, and therefore represented the best solution."],["dc.identifier.doi","10.1636/t04-95.1"],["dc.identifier.gro","3149800"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/6499"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.issn","0161-8202"],["dc.title","Capture Effiency and Preservation Attributes of Different Fluids in Pitfall Traps"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","133"],["dc.bibliographiccitation.issue","1-5"],["dc.bibliographiccitation.journal","The Journal of Steroid Biochemistry and Molecular Biology"],["dc.bibliographiccitation.lastpage","147"],["dc.bibliographiccitation.volume","83"],["dc.contributor.author","Wuttke, Wolfgang"],["dc.contributor.author","Jarry, Hubertus"],["dc.contributor.author","Westphalen, S."],["dc.contributor.author","Christoffel, V."],["dc.contributor.author","Seidlova-Wuttke, Dana"],["dc.date.accessioned","2021-06-01T10:50:19Z"],["dc.date.available","2021-06-01T10:50:19Z"],["dc.date.issued","2002"],["dc.description.abstract","Due to some severe side effects \"classical\" hormone replacement therapy (HRT) is currently being challenged by a therapy with phytoestrogens. Particularly soy and red clover derived isoflavones are advertised as selective estrogen receptor modulators (SERMs) with only desired and no undesired estrogenic effects. Evidence that this is the case however is scarce. Most studies investigating climacteric complaints did not find beneficial effects. A proposed beneficial effect on mammary cancer is unproven. The majority of studies however indicate an antiosteoporotic effect of isoflavones, while putative beneficial effects in the cardiovascular system are questionable due to the fact that estradiol which-like isoflavones-increase HDL and decrease LDL concentrations appear not to prevent arteriosclerosis in the human. In the urogenital tract, including the vagina, soy and red clover derived isoflavones are without effects. Cimicifuga racemosa extracts are traditionally used for the treatment of climacteric complaints. Evidence is now available that the yet unknown compounds in Cimicifuga racemosa extracts prevent climacteric complaints and may also have antiosteoporotic effects. (C) 2003 Published by Elsevier Science Ltd."],["dc.identifier.doi","10.1016/S0960-0760(02)00259-5"],["dc.identifier.isi","000182387400016"],["dc.identifier.pmid","12650710"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86615"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Pergamon-elsevier Science Ltd"],["dc.publisher.place","Oxford"],["dc.relation.conference","15th International Symposium of the Journal of Steroid Biochemistry and Molecular Biology"],["dc.relation.eventlocation","MUNICH, GERMANY"],["dc.relation.issn","0960-0760"],["dc.title","Phytoestrogens for hormone replacement therapy?"],["dc.type","conference_paper"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","159"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Arachnology"],["dc.bibliographiccitation.lastpage","162"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Schmidt, Martin H."],["dc.contributor.author","Clough, Yann"],["dc.contributor.author","Schulz, Wenke"],["dc.contributor.author","Westphalen, Anne"],["dc.contributor.author","Tscharntke, Teja"],["dc.date.accessioned","2018-11-07T10:35:57Z"],["dc.date.available","2018-11-07T10:35:57Z"],["dc.date.issued","2006"],["dc.description.abstract","Pitfall traps are widely used to capture arthropods. The type of fluid employed in the traps can affect size and condition of the catch. Direct comparisons of different fluids allow entomologists to avoid suboptimal solutions, and facilitate comparisons between studies using different fluids. We compared capture efficiency and preservation attributes between five fluids in a field experiment with special respect to spiders (Araneae) and ground beetles (Coleoptera, Carabidae). Catches in pure water, ethanol-water and ethanol-glycerin were less well preserved than in brine or ethylene glycol-water. Brine and ethanol-glycerin showed low capture efficiencies, presumably because their high specific density made arthropods float and thereby facilitated escape. Only the mixture of ethylene glycol and water combined good preservation attributes with high capture efficiency, and therefore represented the best solution."],["dc.identifier.doi","10.1636/T04-95.1"],["dc.identifier.isi","000240304000014"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45213"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Arachnological Soc"],["dc.relation.issn","0161-8202"],["dc.title","Capture efficiency and preservation attributes of different fluids in pitfall traps"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","European Journal of Endocrinology"],["dc.bibliographiccitation.lastpage","14"],["dc.bibliographiccitation.volume","146"],["dc.contributor.author","Grundker, Carsten"],["dc.contributor.author","Gunthert, Andreas R."],["dc.contributor.author","Westphalen, S."],["dc.contributor.author","Emons, G."],["dc.date.accessioned","2018-11-07T10:33:02Z"],["dc.date.available","2018-11-07T10:33:02Z"],["dc.date.issued","2002"],["dc.description.abstract","The expression of GnRH and its receptor as a part of an autocrine regulatory system of cell proliferation has been demonstrated in a number of human malignant tumors; including cancers of the breast, ovary and endometrium. Dose-dependent antiproliferative effects of GnRH agonists in cell lines derived from these cancers have been observed by various investigators. GnRH antagonists also have marked antiproliferative activity in most breast, ovarian and endometrial cancer cell lines tested, indicating that the dichotomy of GnRH agonists and antagonists might not apply to the GnRH system in cancer cells. The classical GnRH receptor signal-transduction mechanisms, known to operate in the pituitary, are not involved in the mediation of antiproliferative effects of GnRH analogs in cancer cells. Rather, the GnRH receptor interacts with the mitogenic signal transduction of growth factor receptors and related oncogene products associated with tyrosine kinase activity; via activation of a phosphotyrosine phosphatase, resulting in downregulation of cancer cell proliferation. In addition, GnRH activates nuclear factor kappaB and protects the cancer cells from apoptosis. Furthermore, GnRH induces activation of the c-Jun N-terminal kinase/activator protein-1 (AP-1) pathway independent of the known AP-1 activators, protein kinase or mitogen activated protein kinase."],["dc.identifier.doi","10.1530/eje.0.1460001"],["dc.identifier.isi","000178742700001"],["dc.identifier.pmid","11751060"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/44505"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Bioscientifica Ltd"],["dc.relation.issn","1479-683X"],["dc.relation.issn","0804-4643"],["dc.title","Biology of the gonadotropin-releasing hormone system in gynecological cancers"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","443"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Onkologie"],["dc.bibliographiccitation.lastpage","446"],["dc.bibliographiccitation.volume","25"],["dc.contributor.author","Weise, M."],["dc.contributor.author","Westphalen, S."],["dc.contributor.author","Fayyazi, Afshin"],["dc.contributor.author","Emons, G."],["dc.contributor.author","Krauss, T."],["dc.date.accessioned","2018-11-07T10:01:48Z"],["dc.date.available","2018-11-07T10:01:48Z"],["dc.date.issued","2002"],["dc.description.abstract","Introduction: Pseudo-Meigs syndrome is a rare syndrome with pelvic tumors (not ovarian fibromas), which is combined with ascites and hydrothorax. Up to now 23 cases of pseudo-Meigs syndrome associated with uterine leiomyomas are described. We present a further case of a young woman with pseudo-Meigs syndrome combined with bladder attachment and elevated CA-125. Case Report: A 27-year-old woman complained about increasing abdominal volume for about 2 months. Clinical results showed a normal sized uterus with a pedunculated leiomyoma, ascites, and a small pleural effusion. CA-125 levels were approximately more than 50 times higher than normal range. An explorative laparotomy revealed a leiomyoma and ascites. The myoma was attached to the posterial wall of the bladder; the rest of the uterus and both adnexae were normal. An organ-preserving operation was performed. Three months afterwards the patient presented normal clinical and sonographical findings and normal CA-125 serum levels. Discussion: Uterine leiomyoma is only rarely associated with ascites and hydrothorax. Our case is the 24th in literature. Like other authors we could show elevated CA-125 serum levels. Cases of pseudo-Meigs syndrome with penduculated myomas and tight adhesions of neighbouring structures have been described frequently. In our case the bladder was tightly attached, and the vascularisation seemed to come from the uterus and the bladder. This atypical double supply might be in etiological context with the ascites. Pseudo-Meigs syndrome should be considered as a rare differential diagnosis for ascites and pleural effusions."],["dc.identifier.doi","10.1159/000067439"],["dc.identifier.isi","000179157100009"],["dc.identifier.pmid","12415199"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38102"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.relation.issn","0378-584X"],["dc.title","Pseudo-Meigs syndrome: Uterine leiomyoma with bladder attachment associated with ascites and hydrothorax - a rare case of a rare syndrome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","552"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Gynecologic Oncology"],["dc.bibliographiccitation.lastpage","559"],["dc.bibliographiccitation.volume","90"],["dc.contributor.author","Verschraegen, C. F."],["dc.contributor.author","Westphalen, S."],["dc.contributor.author","Hu, W."],["dc.contributor.author","Loyer, E."],["dc.contributor.author","Kudelka, A."],["dc.contributor.author","Volker, P."],["dc.contributor.author","Kavanagh, J."],["dc.contributor.author","Steger, M."],["dc.contributor.author","Schulz, Klaus-Dieter"],["dc.contributor.author","Emons, G."],["dc.date.accessioned","2018-11-07T10:36:33Z"],["dc.date.available","2018-11-07T10:36:33Z"],["dc.date.issued","2003"],["dc.description.abstract","Objective: The goal of this work was to study the anticancer activity of cetrorelix, a decapeptide with LHRH receptor antagonist properties in patients with platinum-resistant ovarian cancer. About 80% of primary ovarian cancers and cell lines bear LHRH receptors. Cetrorelix has anticancer activity in in vitro and in vivo ovarian cancer models. Methods. Eligible patients with ovarian or mullerian carcinoma resistant to platinum chemotherapy received cetrorelix 10 mg subcutaneously every day. Eligibility criteria included age greater than or equal to 18, PS less than or equal to 2, measurable disease, chemistries and blood counts in normal range, no estrogen replacement for at least 2 weeks, and no known allergic reactions to extrinsic peptide. In patients volunteering for a biopsy, tissue was taken to perform a LHRH receptor assay. Results. Seventeen patients were treated. Median age was 58 years. Median performance status was 0. Median number of prior chemotherapies was 3. Three patients had partial remissions lasting 9, 16, and 17 weeks. Toxicities effects included grade 4 anaphylactoid reaction (one patient) controlled by cortisol and cimetidine, grade 2 histamine reaction (two patients), grade 2 arthralgia (one patient) 20% cholesterol increase (two patients, who did not require specific treatment), minor hot flushes, headache, and local skin reaction at the injection site. Six of seven samples were LHRH receptor positive for mRNA and/or ligand assay. Two responding patients were LHRH receptor positive. The patient who had no receptor did not respond. Conclusion. Cetrorelix has activity against ovarian cancer in this refractory population, and has minimal toxicity, except for potential anaphylactoid reactions. Activity may be mediated through the LHRH receptor. (C) 2003 Elsevier Inc. All rights reserved."],["dc.description.sponsorship","NCI NIH HHS [R21-CA-72004-02]"],["dc.identifier.doi","10.1016/S0090-8258(03)00408-6"],["dc.identifier.isi","000185521000008"],["dc.identifier.pmid","13678723"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45352"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Academic Press Inc Elsevier Science"],["dc.relation.issn","0090-8258"],["dc.title","Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Naunyn-Schmiedeberg s Archives of Pharmacology"],["dc.bibliographiccitation.volume","365"],["dc.contributor.author","Seidlova-Wuttke, Dana"],["dc.contributor.author","Westphalen, S."],["dc.contributor.author","Metten, M."],["dc.contributor.author","Gamer, A. O."],["dc.contributor.author","Jarry, Hubertus"],["dc.contributor.author","Wuttke, Wolfgang"],["dc.date.accessioned","2018-11-07T10:31:36Z"],["dc.date.available","2018-11-07T10:31:36Z"],["dc.date.issued","2002"],["dc.format.extent","R131"],["dc.identifier.isi","000175030900519"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/44152"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.issn","0028-1298"],["dc.title","Effects of acute i.v. infusion and 5-day styrene inhalation on neuroendocrine function in male rats."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1007"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","GYNAKOLOGE"],["dc.bibliographiccitation.lastpage","1020"],["dc.bibliographiccitation.volume","35"],["dc.contributor.author","Wuttke, Wolfgang"],["dc.contributor.author","Jarry, Hubertus"],["dc.contributor.author","Westphalen, S."],["dc.contributor.author","Christoffel, V."],["dc.contributor.author","Gorkow, C."],["dc.contributor.author","Seidlova-Wuttke, Dana"],["dc.date.accessioned","2018-11-07T09:59:36Z"],["dc.date.available","2018-11-07T09:59:36Z"],["dc.date.issued","2002"],["dc.description.abstract","Due to some severe side effects, \"classic\" hormone replacement therapy (HRT) is currently being challenged by therapy with phytoestrogens. Particularly soy- and red clover-derived isoflavones are advertised as selective estrogen receptor modulators (SERMs) with only desired and no undesired estrogenic effects. Evidence that this is the case however is scarce. Most studies investigating climacteric complaints did not find beneficial effects. A proposed beneficial effect on mammary cancer is unproven. The majority of studies however indicate an antiosteoporotic effect of isoflavones, while putative beneficial effects in the cardiovascular system are questionable due to the fact that estradiol, which - like isoflavones - increases HDL and decreases LDL concentrations, does not appear to prevent arteriosclerosis in humans. In the urogenital tract, including the vagina, soy- and red clover-derived isoflavones exert no effects. Cimicifuga racemosa extracts are traditionally used for the treatment of climacteric complaints. Evidence is now available that the as yet unknown compounds in Cimicifuga racemosa extracts prevent climacteric complaints and may also have antiosteoporotic effects."],["dc.identifier.doi","10.1007/s00129-002-1270-9"],["dc.identifier.isi","000179029700010"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37631"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0017-5994"],["dc.title","Phytoestrogens - an alternative to standard hormone replacement therapy?"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","291"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Endocrine Related Cancer"],["dc.bibliographiccitation.lastpage","299"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Emons, G."],["dc.contributor.author","Grundker, Carsten"],["dc.contributor.author","Gunthert, Andreas R."],["dc.contributor.author","Westphalen, S."],["dc.contributor.author","Kavanagh, J."],["dc.contributor.author","Verschraegen, C."],["dc.date.accessioned","2018-11-07T10:38:30Z"],["dc.date.available","2018-11-07T10:38:30Z"],["dc.date.issued","2003"],["dc.description.abstract","Approximately 80% of human ovarian and endometrial cancers and 50% of breast cancers express GnRH and its receptor as part of an autocrine regulatory system. After binding of its ligand the tumor GnRH receptor couples to G-protein alphai and activates a variety of intracellular signaling mechanisms. (1) Through activation of a protein tyrosine phosphatase, autophosphorylation of growth factor receptors is reverted leading to an inhibition of mitogenic signaling and reduced cell proliferation. (2) Through activation of nuclear factor kappa B antiapoptotic mechanisms are induced protecting tumor cells from apoptosis induced, for example, by doxorubicin. (3) Through activation of the Jun kinase pathway AP-1 is induced, leading to cell cycle arrest in the G(0)/G(1) phase. It seems reasonable to speculate that this system enables the tumor cell to reduce proliferation and to activate repair mechanisms while being protected simultaneously from apoptosis. Interestingly, GnRH antagonists show the same activity in this system as agonists, indicating that the dichotomy GnRH agonist-GnRH antagonist defined in the pituitary gonadotrope is not valid for the tumor GnRH system. Recently, a second type of GnRH receptor, specific for GnRH-II, has been identified in ovarian and endometrial cancers, which transmits significantly stronger antiproliferative effects than the GnRH-I receptor. GnRH antagonists have agonistic effects on this type II receptor. In animal models of human cancers, GnRH antagonists had stronger antitumor effects than GnRH agonists. Therefore, we performed a phase II clinical trial with the GnRH antagonist, cetrorelix (10 mg/day), in patients with ovarian or mullerian carcinoma refractory to platinum chemotherapy. Of 17 evaluable patients treated with cetrorelix, 3 obtained a partial remission (18%) which lasted for 2 to 6 months. Furthermore, 6 patients experienced disease stabilization (35%) for up to 1 year. In this very refractory patient population (median number of prior chemotherapies = 3) these results are quite remarkable when compared with palliative chemotherapy. In addition, cytotoxic GnRH analogs have been developed, where for example doxorubicin was covalently coupled to GnRH analogs. These compounds have superior antitumor effects in cancers expressing GnRH receptors as compared with native doxorubicin and allow for a targeted cytotoxic chemotherapy of gynecologic and breast cancers."],["dc.identifier.doi","10.1677/erc.0.0100291"],["dc.identifier.isi","000184151400018"],["dc.identifier.pmid","12790790"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45828"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Soc Endocrinology"],["dc.publisher.place","Bristol"],["dc.relation.conference","11th International Congress on Hormonal Steroids/7th International Congress on Hormones and Cancer"],["dc.relation.eventlocation","FUKUOKA, JAPAN"],["dc.relation.issn","1351-0088"],["dc.title","GnRH antagonists in the treatment of gynecological and breast cancers"],["dc.type","conference_paper"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1063"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","International Journal of Oncology"],["dc.bibliographiccitation.lastpage","1069"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Westphalen, S."],["dc.contributor.author","Kotulla, G."],["dc.contributor.author","Kaiser, Armin Florian"],["dc.contributor.author","Krauss, W."],["dc.contributor.author","Werning, G."],["dc.contributor.author","Elsasser, H. P."],["dc.contributor.author","Nagy, A."],["dc.contributor.author","Schulz, Klaus-Dieter"],["dc.contributor.author","Grundker, Carsten"],["dc.contributor.author","Schally, Andrew V."],["dc.contributor.author","Emons, G."],["dc.date.accessioned","2018-11-07T11:24:26Z"],["dc.date.available","2018-11-07T11:24:26Z"],["dc.date.issued","2000"],["dc.description.abstract","Eighty percent of human ovarian and endometrial cancers express receptors for luteinizing hormone-releasing hormone (LHRH). These receptors might be used for targeted chemotherapy with cytotoxic LHRH analogs such as AN-152, in which doxorubicin is linked to agonist carrier [D-Lys(6)]LHRH. The antiproliferative effects of doxorubicin and AN-152 were assessed in LHRH receptor-positive ovarian (EFO-21, EFO-27) and endometrial (HEC-1A, Ishikawa) cancer cell lines as well as in LHRH receptor negative ovarian SKOV-3 and endometrial MFE-296 lines. The mechanism of action of AN-152 was investigated by a blockage of receptors using an excess of the LHRH agonist [D-Trp(6)]LHRH. In some cases, confocal laser-scanning microscopy was used to visualize the accumulation of AN-152 or doxorubicin within the cells. In 3 of 4 LHRH receptor-positive cell lines (EFO-21, HEC-1A, Ishikawa) AN-152 was more effective than doxorubicin in inhibiting cell proliferation. The effect of AN-152 was shown to be receptor-mediated because it could be reduced by competitive blockade of the LHRH receptors with [D-Trp(6)]LHRH. In contrast, AN-152 was less active than doxorubicin in LHRH receptor-negative lines. Confocal laser-scanning microscopy showed an intranuclear accumulation of AN-152 and competitive inhibition thereof by [D-Trp(6)]LHRH in LHRH receptor-positive cell lines, but no intracellular accumulation of AN-152 could be detected in the receptor-negative SKOV-3 line. These results suggest a selective receptor-mediated action of AN-152 in receptor-positive cell lines."],["dc.identifier.isi","000089825300028"],["dc.identifier.pmid","11029513"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56405"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Professor D A Spandidos"],["dc.relation.issn","1019-6439"],["dc.title","Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]